Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
about
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeEuropean perspective on multiple myeloma treatment strategies in 2014Trial Watch: Proteasomal inhibitors for anticancer therapyDiseaseConnect: a comprehensive web server for mechanism-based disease-disease connections.Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Allogeneic stem cell transplantation for multiple myeloma: is there a future?Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.
P2860
Q26782868-A2B7AEA3-B1A1-443B-A579-1B54E67F2324Q27005966-51F1CDFF-FD82-45F4-B959-569B5925525BQ28082910-D713326F-B823-46C3-B43F-3F9786452F9FQ33860701-54792FD8-45FD-4ABD-8978-08D783987819Q36000415-10F81BAF-E585-4D8C-974C-AB018E8D10C6Q38417073-D2655F6B-5A16-444F-95FB-C54EB04E5BCEQ38685796-CBFD66A9-C64A-49AA-BD10-DAC8E864EB42Q38688055-8F218944-E969-44E4-B1AB-D4F4BFBF6F3EQ39174731-BBE12069-28C0-47E8-8CAF-784B7BEAD325Q39307476-6B9E51E4-956B-4468-B0F3-5E138E9D9E76Q39425529-4AE3D9EF-58D3-41F4-80E0-5BB18C17789EQ41522018-AAF52E0C-29D6-4CC3-8823-DA01D29E55F4Q47794767-8560CC09-D0A3-42F3-BEE5-48E153D5B5B5Q52912068-6A521234-54AF-4A90-A76E-E54C879E819BQ55026920-E04212A4-E91E-41B7-946D-C3F668257F04
P2860
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Phase II clinical trial for th ...... or high-risk myeloma patients.
@en
Phase II clinical trial for th ...... intensity conditioning regimen
@nl
type
label
Phase II clinical trial for th ...... or high-risk myeloma patients.
@en
Phase II clinical trial for th ...... intensity conditioning regimen
@nl
prefLabel
Phase II clinical trial for th ...... or high-risk myeloma patients.
@en
Phase II clinical trial for th ...... intensity conditioning regimen
@nl
P2093
P2860
P356
P1476
Phase II clinical trial for th ...... or high-risk myeloma patients.
@en
P2093
Antonia Sampol
Cristina Castilla-Llorente
Cristina Encinas
David Serrano
Dolores Caballero
Inmaculada Heras
Jesús San Miguel
José A Pérez-Simón
Laura Rosiñol
Lucia López-Corral
P2860
P304
P356
10.1111/BJH.12410
P407
P577
2013-06-15T00:00:00Z